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INTRODUCTION 
             Brachial plexus blocks provides a useful alternative to general anaesthesia for 
upper limb surgeries. They achieve near ideal operating conditions by producing good 
muscular relaxation, maintaining stable haemodynamics and associated sympathetic 
block. The sympathetic block reduces the postoperative pain, vasospasm and edema. 
             Although various anaesthetic agents have been used, bupivacaine is a better 
choice due to its longer duration of action of 3 to 8hrs. However it has certain 
disadvantages like delayed onset, patchy or incomplete analgesia etc, 
              Various adjuvants like neostigmine, midazolam, opioids etc,(1-4)  have been 
tried to improve the onset of block, quality of block, prolong the duration of block and 
postop analgesia. But these were associated with side effects. 
               Clonidine an alpha-2 agonist which had been used as antihypertensive 
initially has sedative, sympatholytic and analgesic properties. It is also known to have 
anti nociceptive action and enhances the effect of local anasthetics when given 
intrathecally, epidurally and in peripheral nerve blocks. This effect is produced by 
modulating pain pathways through presynaptic alpha-2 adrenergic receptors. It also 
produces sedation through its action on pontine locus ceruleus where highest number 
of  alpha-2 receptors are present. 
             Dexmedetomidine, the next recent highly potent alpha-2 agonist, is also a 
sedative, anxiolytic and analgesic similar to clonidine. The peculiar features of 
 
 
dexmedetomidine is its high selectivity for alpha-2 receptors and its ability to produce 
sedation and analgesia while still maintaining patient arousability and respiratory 
function. 
                So the present study has been undertaken as randomized single blinded 
manner to compare the onset time, duration and analgesic efficacy of clonidine with 
dexmedetomidine when added as adjuvant to bupivacaine(0.25%) for brachial plexus 
block by supraclavicular approach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVES 
• This study of adding clonidine (1µg/kg) or dexmedetomidine (1µg/kg) to 
bupivacaine (0.25%) in brachial plexus block for  surgeries involving the upper 
limb has the following objectives: 
• To compare the 
o Onset of sensory and motor blockade 
o Duration of sensory and motor blockade 
o Sedation score intra and postoperatively 
o Haemodynamic variables (HR,BP,SPO2) 
o No of rescue analgesics in postoperative 24hrs 
between clonidine and dexmeditomedine. 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
          To compare the effectiveness of clonidine and dexmedetomidine as adjuvant 
in brachial plexus block by supraclavicular approach for prolongation of sensory 
and motor blockade and duration of analgesia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
HISTORY(5-7) 
1858 – theory of pain as a separate and distinct sense was formulated by Mortiz 
S.Schiff. 
 1885 – the first brachial plexus block was performed by William Stwart Halsted 
and Alfred Hall – idea of injecting cocaine into nerve trunk in 1885, less than a 
year after Koller demonstrated the anaesthetic properties of cocaine on the eye of a 
patient. 
1897 – Crile used a similar trchnique in which the plexus was exposed under local 
anaesthesia. Just behind the sternocleidomastoid, cocaine was injected into the 
nerve trunks under direct vision which was done as a therapeutic measure in a 12yr 
old boy who developed tetanic spasms following a compound fracture of the 
forearm, after which it was used to provide anaesthesia for  surgeries in the upper 
limb. 
EVOLUTION OF SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK: 
1911 – 1912 – KULENKAMPFF performed the first percutaneous supraclavicular 
approach. He pointed out that above the clavicle the plexus lies under the skin as it 
passes over the first rib and accessible to a percutaneous technique. 
 
 
1922 – LABAT injected at three separate points, first beneath the deep fascia 
towards the first rib, second towards the chassaignac’s tubercle and third towards 
the lateral margin of the first rib behind the clavicle. 
1926 – LIVINGSTON proved that the plexus and the artery are separated by a 
fascial investment. 
1940 – PATRICK chose to deposit the anaesthetic along the plexus in its course 
over the first rib where 60-70ml of solution was injected during 5-6 insertions. The 
technique became the ‘standard technique’ of supraclavicular block, subsequently 
reffered to many as ‘classical supraclavicular technique’. 
1942 – KNIGHT modified Patrick’s technique by using three needle insertions. 
1944 – MURPHEY used a single injection technique by using the lateral border of 
anterior scalene muscle as the landmark. 
1949 – BONICA AND MOORE followed the ‘walking the rib’ method using 
Kulenkampff and Patrick’s technique which was used over the subsequent twenty 
years. 
1958 – LOOKMAN like Livingston realized the fascial investment of the plexus 
and identified that it lies between the anterior and the middle scalene muscles, but 
passed the needle too posteriorly . 
 
 
1964 – WINNIE showed that the relation of the plexus and the subclavian artery to 
the midpoint of the first rib is not constant, but there is a constant relationship 
between the scalene muscles, plexus and the first rib. The plexus between the two 
scalene muscles always inserted on the first rib. He inserted needle between the 
two muscles in the direction of the space between them. Once paresthesia is 
elicited he injected the drug into the space.  
 
 
 
 
 
 
 
 
 
 
 
 
 
ANATOMY OF BRACHIAL PLEXUS(8-11) 
            Knowledge of the formation of brachial plexus and of its distribution is  
essential to the intelligent and effective use of brachial plexus anesthesia for 
surgeries of the upper limb. Close familiarity with the vascular, muscular and 
fascial relationships of the plexus throughout its formation and distribution is 
equally important.  
While travelling from the intervertebral foramina to the upper limb, the fibres that 
constitute the plexus are composed of roots, trunks, divisions and terminal nerves. 
FORMATION OF BRACHIAL PLEXUS:  
           The plexus is formed by the anterior primary rami of the 5th to 8th cervical 
nerves, together with the bulk of the 1st thoracic nerve (C – 8 and T -1). In addition 
there might be a contribution above from 4th  to  5th cervical root and another below 
from 2nd to 1st thoracic nerve. Occasionally the plexus is may also be derived from 
C4 to C8 (pre-fixed plexus) or from C6 to T2 (post-fixed plexus). 
 
 
 
 
 
 
 
 
Fig. 1: Formation of brachial plexus 
 
 
 
Fig.2: Relation of brachial plexus 
 
 
 
 
 
Roots: 
           Represents the anterior primary divisions of lower four cervical and first 
thoracic nerves. They emerge from the intervertebral foramina and fuse above the 
first rib to form the trunks. 
Trunks: 
           The roots combine above the first rib to form the three trunks of the plexus. 
C5 and C6 unite to form the upper trunk. C8 and T1 unite behind the scalenus 
anterior to form the lower trunk and C7 continues as a sole contributor to form the 
middle trunk. 
Divisions:  
           As the trunks pass above the first rib and below the clavicle, each one of 
them divides into anterior and posterior divisions. 
Cords: 
              The fibres as they emerge from under the clavicle, again combine to form 
the three cords. The anterior divisions of the upper and the middle trunks forms the 
lateral cord, lateral to the axillary artery. The medial cord is formed by the anterior 
division of the lower trunk which descends medial to the axillary artery .The 
posterior cord is formed by the posterior divisions of all three trunks, behind the 
axillary artery. 
 
 
         The medial and lateral cords supply the flexor surface of the upper extremity, 
whereas nerves from the posterior cord supply the extensor surface. 
Major terminal nerves: 
           Each of these cords gives rise to one of the major nerves of the upper 
extremity and then terminate as a major nerve. The lateral cord gives off  the 
lateral head of the median nerve and the medial cords give off the medial head of 
the median nerve and continue as major terminal nerves.  The lateral cord 
terminates as musculocutaneous nerve and the medial cord as the ulnar nerve. 
Posterior cord branches off as axillary nerve and continues as radial nerve. 
         In summary, conveniently it can be considered that the brachial plexus begins 
with five nerves (C5 to T1) and terminates as five nerves (musculocutaneous, 
axillary, radial, median and ulnar nerves) with its intermediate portions displaying 
into 2 sets of three, which reunite and give rise to three cords. These three cords 
gives off three lateral branches before becoming the major terminal branches of the 
plexus. 
Distribution of the brachial plexus: 
             These are divided into those that arise above the clavicle the 
supraclavicular branches and those that arise below it, the infraclavicular branches. 
 
 
 
Supraclavicular branches: 
From roots 
1. Nerve to scalene and longus colli muscle – C5,6,7,8 
2. Branch to phrenic nerve – C5 
3. Dorsal scapular nerve – C5 
4. Long thoracic nerve of Bell – C5,6,(7) 
From trunks: 
1. Nerve to subclavius muscle – C5,C6 
2. Suprascapular nerve – C5,C6 
Infraclavicular branches: 
They branch from cords but their fibres may be tracked back to spinal nerves. 
Lateral cord: 
1. Lateral pectoral nerve – C5,6,7 
2. Musculocutaneous nerve – C5,6,7 
3. Lateral root of median nerve – C5,6,7 
Medial cord: 
1. Medial pectoral nerve – C8,T1 
2. Medial cutaneous nerve of forearm – C8,T1 
 
 
3. Ulnar nerve – C7,T1 
4. Medial root of median nerve – C8,T1 
5. Medial cutaneous nerve of arm – C8,T1 
Posterior cord: 
1. Upper subscapular nerve – C5,6 
2. Thoracodorsal nerve  - C6,7,8 
3. Lower subscapular nerve – C5,6 
Sympathetic contribution to brachial plexus: 
          The segmental preganglionic sympathetic contributions are variable, but 
generally extend more caudal. The highest contribution is T2 with T1 contributing 
very rarely, while lowest may be as far as T8, T9 or even T10. The postganglionic 
contributions are from grey rami communicants from the sympathetic chain. 
RELATIONS OF THE BRACHIAL PLEXUS 
Roots: Lies between the scalenus anterior and medius above the second part of the 
subclavian artery. 
Trunks: The upper and the middle trunks lie above the subclavian artery as they 
stream across the 1st rib, but the lower trunk lies behind the artery and may groove 
the rib immediately posterior to the subclavian groove. 
 
 
Divisions: At the lateral border of the first rib, the trunks bifurcate into divisions, 
which are situated behind the clavicle. 
Cords: The cords are found at the apex of the axilla and become grouped around 
the axillary artery. 
The interscalene sheath: 
         As the roots C5 – T1 emerge in the groove between the transverse process and 
the tubercles, they lie in the fibro-fatty space between the two layers of fibrinous 
sheath. Posterior sheath from the posterior tubercle covers the front of the scalenus 
medius and anterior sheath from the anterior tubercle covers the posterior aspect of 
scalenus anterior. The sheath extends into the axilla around the plexus. 
Significance of this space is that the local anaesthetic can be injected into this 
sheath to produce block either by interscalene, subclavian perivascular or axillary 
approach.            
TECHNIQUE OF BRACHIAL PLEXUS BLOCK 
            Surgical anesthesia for the upper extremity and shoulder can be obtained by 
blocking the brachial plexus at various sites. There are various approaches that can 
be used for this blockade as follows 
     1.Interscalene approach 
2.Supraclavicular approach 
 
 
   a.Classic approach 
   b. Plumb – bob technique 
   c.Subclavian perivascular technique 
3.Axillary approach 
4.Infraclavicular approach 
Complications: 
1. Intravascular injection 
2. Pneumothorax 
3. Phrenic nerve block 
 
 
 
 
 
 
 
 
 
 
 
PATHOPHYSIOLOGY OF PAIN 
Definition of Pain: 
 The Taxonomy Committee of International Association for the study of Pain 
(IASP) defines pain as "An unpleasant sensory and emotional experience 
associated with potential tissue damage or described in terms of such damage".  
Postoperative pain is defined as a form of acute pain caused by surgical trauma 
with an inflammatory reaction and with initiation of an afferent neuronal barrage.  
Physiology of pain: 
 The spinal cord conveys signal from the brain to the nerves located 
throughout the body. Nerves coming from the spinal cord and leading to all parts 
of the body enter and leave the spinal cord along its entire length. There are 31 
pairs of spinal nerves that leave the spinal cord through the intervertebral 
foraminae. The peripheral nerves includes motor and sensory nerves. Sensory 
nerves are that which receive and transmit sensory stimuli to Substantia gelatinosa. 
Motor nerves are those which lead to the muscles and stimulate movement of 
muscles. 
 
 
 
 
 
Various mechanisms are:   
          Nociception refers to the perception  of a noxious stimulus by the brain.(13) 
The components  include transduction,  modulation, transmission and perception 
(fig.4).  
 
 
                            
Fig. 3: Process of Nociception 
Peripheral sensitization.  
Central sensitization  
Pathways of pain:  
 Pain is conducted along neuron pathways that transmits the noxious stimuli 
from periphery to cerebral cortex. 
 
 
 
 
 
 
 
 
 
                        
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Normal pathways of pain 
 
 A first order neuron, arising in the cell body in dorsal root ganglion of the 
spinal cord transmits pain from a peripheral receptor to the dorsal horn of the 
spinal cord.                                                                                                         
 A second-order neuron is located in the dorsal horn of the spinal cord and 
sends axons that crosses the midline to ascend as the spinothalamic tract to 
the thalamus.   
 
 
 A third-order neuron in the thalamus projects its fibers to the post central 
gyrus through the internal capsule.  
Physiological responses to pain:  
It has been found that uncontrolled pain in post operative period produce 
physiological effects like altered stress response to surgery, increased 
catecholamines, deep vein thrombosis, higher incidence of pulmonary 
complications, and ultimately increasing the morbidity.(15-17)  
Peripheral α2 receptors: 
           α2 adrenoceptors are located on primary afferent terminals, on neurons in 
the superficial laminae of the spinal cord, and within several brainstem nuclei 
implicated in analgesia, supporting the possibility of analgesic action at peripheral, 
spinal and brainstem sites. 
          Clonidine enhances both sensory and motor blockade from peripheral nerve 
injection and epidural/spinal injection of local anaesthetics. It also blocks the 
conduction of C and A gamma fibres and increases the potassium conductance in 
isolated neurons and intensifies conduction block of local anaesthetics. 
 
ASSESSMENT OF PAIN  
   It is important in an effective postoperative pain management. Numerous  
pain assessment scales are there to quantify pain.(21,22) The intensity of pain should  
be assessed as far as possible by the patient himself as long as he is able to 
 
 
communicate and expressed what he feels like. A number of self-assessment scales 
are available. 
Visual analogue scale (VAS)   : 
  VAS is the most commonly used method to assess pain which was first 
described in 1966. It is a very simple  and used in pain research. It consists of a 10 
cm line with two anchor points starting from ‘no pain’ to ‘worst pain imaginable’ 
which is self assessed by patient (fig.5). It is the position of the mark on the line 
that measures how much pain the subject experiences. 
                                                                                                                                              
 
 
 
 
 
Fig. 5: Wong‐ Baker Faces pain rating scale and Visual Analogue scale 
 
                                                                                                                                                                                                          
                                                                                                                                                                               
 
 
 
Fig.6 : Numerical Rating Scale 
 
 
 
Others are: 
• Facial expressions:  
This is a pictogram of six faces with different expressions from smiling 
or happy to tearful which can also be used(fig.5). 
• Numerical rating scale (NRS): 
This is similar to the visual analogue scale with the two anchors starting 
from  ‘no pain’ to ‘worst pain as from 0 to 10, assessed by patient (Fig. 
6). 
• Verbal rating scale (VRS) 
                 The preoperative personality assessment is also helpful in assessing the 
patient’s psychological background and his psycho reactions to surgery and the 
pain that follows it. The VRS and NRS are the other mostly used assessment tools 
in the clinical setting while the VAS scale is primarily used as a research too. 
 
METHODS OF ACHIEVING PAIN RELIEF: 
“Pain relief has always been bought at a Price” – Bromage 
                 Number of factors are there that contribute to effective postoperative 
pain management like a structured acute management team, regular staff training, 
 
 
patient education, regular pain assessment tools and use of balanced analgesia to 
meet the needs of special patient groups.  
       Following any surgery, the pain after the tissue damage is usually  self 
limiting. It persists at the most for the first 24 hrs and mostly subsides in 4 days 
time.44 The post operative pain is dull in nature, aggravated by mobility and 
relieved by rest to that part.  The acute pain of surgery is strongly accompanied by 
emotional elements of fear, anxiety, and depression of previous experience of pain.  
The goals of effective and appropriate pain management are to: 
 Facilitate rapid recovery and return of full function. 
 Reduce morbidity.   
 Improve the quality of life for the patient. 
 Allow early discharge from the hospital. 
Methods adopted for providing post operative pain relief include: 45-50 
Pharmacological methods: -  
i. Balanced (multimodal) analgesia  
ii. Opioids  
iii. Non-opioids (NSAIDS) 
iv. Adjuvants  
v. Patient controlled analgesia 
vi. Regional analgesia 
Continuous Central Neuraxial Blockade (CCNB)  
 
 
Continuous Peripheral Nerve Blockade (CPNB)  
Infiltration blocks 
II. Non pharmacological methods: - This includes 
A. Transcutaneous Electrical Nerve Stimulation (TENS) 
B. Acupuncture 
C. Cryotherapy  
D. Heat Therapy  
Regional analgesia:  
Central neuraxial block involves either intermittent or continuous 
administration of local anaesthetics in order to interrupt sensory transmission.49 
The important draw back of this technique is the accompanying motor and 
sympathetic blockade which can increase the incidence of post operative 
complications. Extradural block offers complete pain relief, permits effective 
coughing & better ventilation.  But the total spinal, accidental dural punctures are 
more with inexperience hands. 
        Peripheral nerve blocks are being increasingly used since they may 
provide more selective but still excellent postoperative analgesia with reduced 
need for opioids over an extended period. Peripheral nerve blocks (PNBs) avoid 
the side effects associated with central neuraxial blockade, such as hypotension 
and wide motor blockade with reduced mobility and proprioception, and 
complications such as epidural haematoma, epidural abscess and paraparesis. 
 
 
PHARMACOLOGY 
Local Anaesthetic Drugs: 
          Local anesthetics are drugs that produce reversible conduction 
blockade of nerve impulses along the central and peripheral pathways after 
regional anaesthesia. They produce autonomic, sensory and motor blockade of 
the area innervated by the affected nerve. Removal of the local anaesthetic 
results in complete return of nerve conductions with no structural domage to the 
nerve fibres. 
They have similar configurations with one aromatic lipophilic part 
(Benzene ring) and one hydrophilic part (quaternary ring) connected by an 
intermediate ring either ester (-coo-) or an amide (-NHCO-). 
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Physiochemical properties: 
1. Molecular weight: of chloride salt is 325 and of its base form is 288. 
2. pKa: 8.1  
3. Protein binding: 95% 
4. Solubility: The base is sparingly soluble and the hydrochloride salt is 
readily soluble in water. 
5. Partition coefficient: 28 
6. T1/2: 210min 
7. Clearance: 0.47L/min 
8. Moderate onset and long action. 
Mechanism of action: It acts on the cell membrane of the axon producing 
electrical stabilization. The permeability to sodium ions necessary for impulse 
propagation is prevented. Thus resting membrane potential is maintained and 
depolarization is inhibited. 
        The local anaesthetics block the sodium conductance by the following 
mechanisms: 
 
 
1. Local anaesthetics in the cationic form act on the receptors within the 
sodium channels, on the cell membrane and block it. They reach the 
sodium channels via the lipophilic pathway directly across the lipid 
membrane or via the axoplasmic opening. This mechanism is responsible 
for 90% of nerve blocking effect of amide local anaesthetic. 
2. The second mechanism is by membrane expansion, which is a non 
specific action in contrast to more specific drug receptor interaction. 
Available concentrations: 
• 0.25%  and 0.5% 
• 0.25% and 0.5% soluble in isotonic saline – isobaric  
• 0.5% soluble in 8% dextrose – hyperbaric 
These doses may be repeated in three to four hours but the maximum dose is 
400mgs. Addition of a vasoconstrictor produces very little increase in duration 
of action, but significantly reducing the peak blood levels decreasing the 
systemic toxicity. 
 
 
 
Actions: 
CNS effects are characterized by excitation or depression. The intial 
manifestation may be nervousness, dizziness, blurring of vision or tremors 
followed by drowsiness, convulsions and unconsciousness. In CVS, it produces 
reduction in the maximum rate of depolarization in the purkinji fibres and 
ventricular muscles. Action potential duration and effective refractory period is 
also decreased. The rate of recovery is also slower with bupivacaine. Therefore 
there is incomplete restoration of V-max between action potential particularly at 
higher heart rates. Hence,it is highly arrythmogenic.  If excessive plasma level 
is reached, it produces respiratory depression. 
Pharmacodynamics: 
Onset – 4-6min 
Peak effect – 15-20min 
Average duration – 3.5-5hrs, for nerve blocks – 5-6hrs                    
Toxicity: The toxic plasma concentration is 4-5µ/ml. But it rarely approaches 
 
 
the toxic levels. Local irritant effects on the nerve tissue has been noted but 
permanent nerve damage has not been found in clinical dosage. 
Pharmacokinetics: 
          It reaches the blood within 5 min, but the plasma are related to the dosage 
administered. In plasma, it binds avidly to alpha 1 acid glycoprotein to the 
extent of 70-95%. Conversely its unbound active form is one third that of 
lidocaine. 
Metabolism and elimination:                                                                                                   
As it is an amide it is primarily metabolised in the liver by n-dealkylation to 
pipecolyloxylidine. It crosses the placental barrier, but the lowest level of 
placental diffusion has been reported (umbilical vein to maternal ratio – 0.31 to 
0.44). No effect on fetus has been reported so far. 
             10% of the drug is excreted unchanged in urine within 24hrs and 5% as 
pipecolyloxylidine. 
 
 
 
 
Adverse reactions: 
        Might be due to inadvertent iv injection or slow metabolic degradation, 
producing its effects on CNS & CVS. CNS effects include nervousness, 
dizziness, tremors or blurring of vision followed by convulsion and 
unconsciousness. CVS manifestations include myocardial depression, 
hypotension and cardiac arrest. Allergic reactions such as utricaria, 
bronchospasm and hypotension can also occur. 
         Treatment is symptomatic maintaining ventilation and circulation with 
oxygen, controlled ventilation and iv fluids and vasopressors for circulation. 
Diazepam (0.1 – 0.2mg/kg) or thiopentone (2-3mg/kg) can be used for 
convulsions and corticosteroids for allergic reactions. For ventricular fibrillation 
or tachycardia, amiodarone (5mg/kg) or defibrillation (2-5joule/kg) can be used. 
Cardiovascular collapse/CNS ratio: 
The CC/CNS ratio for bupivacaine is 3.5± 0.5or findings indicating that three 
times the drug was required to induce irreversible cardiovascular collapse as 
was needed to produce convulsions. It has also been suggested that some of the 
cardiac toxicity is due to myocardial depression.  
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Physiochemical properties: 
Molecular weight is 266.56 
It is odourless, bitter, white and crystalline substance soluble in water. 
Available as 1ml ampoule containing 150µgs.  
It should be stored below 25⁰C. 
           Clonidine is a centrally acting partial α2 adrenergic agonist having a 
selectivity ratio of 220:1 in favor of α2 receptors. There are three subtypes of α2 
receptors α2a, α2b, α2c. Of these sedation, analgesia and sympatholysis are 
mediated via α2a receptors, vasoconstriction and anti-shivering via α2b 
receptors and a startle response may reflect activation via α2c receptors. This 
startle response includes a physical movement away from the stimulus  and 
breathing changes. It acts on the α2 receptors which are found densely in the 
locus ceruleus in pons and also stimulates the α adrenergic inhibitory neurons in 
the medullary vasomotor centre and inhibits sympathetic outflow from the CNS 
to the peripheral tissues.  
             It modifies the potassium channels in the CNS and hyperpolarises the 
cell membranes producing a profound decrease in anesthetic requirement. 
 
 
Neuraxially it inhibits spinal substance P release and thereby inhibiting the 
nociceptive neuronal firing. Its acts on α2 afferent terminals situated in the 
superficial lamina of the spinal cord and brain stem nuclei and produces 
analgesic effects after neuraxial administration. It also acts on the central 
thermoregulatory system and decreases  the threshold to cold stimuli. 
Pharmacological effects:  
                IV clonidine causes a transient rise in BP by α2 agonistic action on the 
vascular smooth muscle of the skin and mucosa, followed by a decrease in BP 
due to its central α2 action. 
Pharmacokinetics: 
Well absorbed orally and 100% bioavailable. 
Peak plasma concentration is achieved within 60 – 90min.  
Plasma half life 9 – 12hrs. 
Plasma protein binding – 20 – 40%. 
Metabolism – minor pathways with major metabolite, P-hydroxyclonidine 
Excreated in an unchanged form by the kidney. 
 
 
A transdermal delivery system is available in which the drug is released 
constantly for about a week. 
Dosage regimen: 
Oral                  : 3-5µg/kg 
Intranasal        : 2-4µg/kg 
Intramuscular: 2µg/kg 
Intravenous    : 1-3µg/kg 
Spinal              : 50-100g 
Epidural          : 1-2µg/kg 
Transdermal  : 3mg/day 
Precautions: 
• In patients with renal insufficiency, lower dose is needed. 
• Sudden withdrawal produces hypertensive crisis, hence discontinued 
gradually over 2-4 days. 
• Use with caution in patients with cerebrovascular or coronary disease. 
• If a patient with β blocker is on continuous epidural, those drugs should 
be withdrawn several days before discontinuation of epidural. 
 
 
 
Contraindications: 
• Known hypersensitivity to clonidine. 
• Bradyarrythmias or AV block. 
• Cardiovascular disease/hemodynamic instability. 
Interactions: 
• Clonidine  potentiates the CNS depressive effect of alcohol , barbiturates 
or other sedatives. 
• Narcotics also potentiate the hypotensive effects of clonidine. 
• Tricyclic anti-depressants  antagonizes the hypotensive effects of 
clonidine. 
• Drugs with negative chronotropic effect can potentiate bradycardia. 
• Epidural clonidine  prolongs  the duration of epidural local anaesthetics, 
opoids, neostigmine, etc,. 
Uses: 
• Premedication:  
o Oral clonodone is used in a dose of 5µg/kg. 
 
 
• This blunts stress response during laryngoscopy or intubation. Intra-
operative hemodynamic stability, intravenous and inhaled anaesthetic 
drug requirement is reduced. 
• Epidural block:  
Solely or in combination provides excellent analgesia in labor. 
Indicated for treatment of intractable pain which is unresponsive to 
opoids or reflux sympathetic dystrophy or neuropathic pain. 
• Spinal anaesthesia:  
         Combined with local anaesthetics, it improves the quality and 
duration of block, minimizes tourniquet pain and prevents shivering. 
• Caudal anaesthesia: 
          Clonidine with LAs ,increases the duration of anaesthesia and 
analgesia. 
• Perpheral nerve block:  
          Clonidine prolongs the duration of anesthesia and analgesia with 
LAs by 2 times in a dose of 75 - 150µgs. 
 
 
 
• Bier’s block:  
          Enhances the tolerance of tourniquet. 
• Decreasing MAC of sevoflurane: 
          Oral clonidine in a dose of 4µg/kg given 2hrs before induction 
decreases the MAC values of sevoflurane for LMA insertion. 
• Post-Op Nausea and Vomiting (PONV): 
           Oral clonidine of 4µg/kg before surgery enhances the anti-emetic 
effect of propofol when compared with midazolam. 
• Other uses: 
            Protection against myocardial ischemia. Used to diagnose 
pheochromocytoma by administering 0.3mg of clonidine which will 
decrease concentration of catecholamines in normal patients but not in 
pheochromocytoma. At a dose of 75µg IV, it stops shivering by 
thermoregulatory control. Used to treat opoid and alcohol withdrawal 
syndrome. 
 
 
 
 
 
 Side effects: 
• CVS: Orthostatic symptoms, palpitation & tachycardia/bradycardia. 
Syncope, congestive heart failure, Raynaud’s phenomenon, and 
electrocardiographic changes (sinus node arrest, AV block, junctional 
bradycardia, and arrhythmias) have been reported  but rarely. 
CNS: Nervousness, agitation, mental depression, insomnia occur 
commonly and behavioral changes, visual and auditory hallucinations, 
restlessness, anxiety and delirium have also been reported but rarely. 
• Others include rash, pruritis, utricaria, alopecia, nausea and vomiting, 
anorexia and malaise and mild abnormalities in liver function tests.  
• Decreased sexual activity, loss of libido, impotence, nocturia and urinary 
retention, thrombocytopenia, weight gain, gyenacomastia, transient 
elevation of blood glucose and serum creatine phosphokinase  have also 
been reported. 
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Physiochemical properties: 
• Molecular weight:236 
• White powder which is freely soluble in water. 
• Pka:7.1 
• available as a clear, isotonic solution with pH of 4.5 – 7 
• Supplied in one or two ml ampoules containing 100µ of 
dexmedetomidine in water. 
• Solution is preservative free. 
Mechanism of action: 
               α2 receptors are found in the central and peripheral nervous 
systems. They are also found in the platelets and many other organs 
including the liver, kidney, pancreas, and eye. Stimulation of these 
receptors in the spinal cord and brain inhibits neuronal firing causing 
hypotension, bradycardia, sedation and analgesia . The response in other 
organs include decreased secretions, decreased bowel motility, 
glomerular filtration is increased, inhibition of rennin release with 
increased secretion of sodium and water in the kidney. There is also 
 
 
decrease in the  intraocular pressure and decreased insulin release from 
the pancreas. It differs from clonidine in its selectivity for α2a subtype 
receptor causing more effective sedation and analgesia. 
            Majority of patients who received dexmedetomidine were 
sedated, but easily arousable, which is a unique feature not found in 
other sedative. 
Pharmacodynamics: 
              Does not have any direct effect on the heart. It produces a 
biphasic response in CVS , where a bolus of 1µ/kg results in a transient 
rise in BP with a reflux fall in heart rate, especially in younger  patients 
which is found to be due to stimulation of β2 receptors in the vascular 
smooth muscles and can be reduced  by a slow infusion. This was due to 
inhibition of central sympathetic outflow. The norepinephrine release is 
decreased due to stimulation of  alpha 2 receptors resulting in fall in BP 
and HR. These effects may be observed in the post-operative period and 
can easily be managed with  ephedrine, atropine and volume infusion. 
 
 
              The respiratory depression caused by dexmedetomidine has 
been reported to be much lower than other sedatives. 
Pharmocokinetics: 
          It undergoes almost complete hydroxylation via direct 
glucuronidation and cytochrome P450 metabolism in the liver. 
           Metabolites are excreted in the urine (95%) and in the feces (4%). 
Its elimination half life is 2hrs, hence making it  necessary to decrease 
the dose in patients with renal failure and hepatic failure. 
Uses: 
It produces anxiolytic, sedative, analgesic and sympatholytic effects, 
hence used for premedication in patients in whom pre-operative stress is 
undesirable. 
Found as an effective premedication before iv regional anaesthesia, as it 
reduces sympathoadrenal responses, patient anxiety, and opioid 
requirement. 
 
 
For intra-operative period, it is used in the dose of 0.2 – 0.7µ/kg/hr like 
clonidine, it attenuates the stress induced sympathoadrenal responses to 
laryngoscopy, intubation and surgery as well as  provides increased 
hemodynamic stability. 
Potentiates the effects of all intra-operative anaesthetics,  whatever  the 
method of administration may be. 
Dexmedetomidine should not be used  in intracranial pathologies till  its 
safety is proved by further studies. 
Also provides  analgesia during the post-operative period.  Also reduces 
the  post-operative analgesic requirements  by 50% in cardiac patients 
and the need for rescue midalozam for sedation was reduced by 80%. 
However it may lack amnestic properties since a small no of patients 
were able to recall their ICU stay. It seems to have very  few respiratory 
side effects, it can be used safely in the extubated patients, 
spontaneously breathing patients. Like clonidine, it is also associated 
with lower rate of shivering. 
 
 
Clonidine on epidural/subarchnoid administration produces analgesia 
partly by causing spinal acetylcholine and nitric oxide release similar to 
which dexmedetomidine also produces dose-dependent analgesia with 
similar potency, but it is less dependent on acetylcholine-NO mechanism 
than clonidine. 
In ICU it is used as sedative, analgesic and anxiolytic as it does not 
produce respiratory depression due to its non-opioid mechanism of 
analgesia. It is generally initiated in a loading infusion dose of 1µ/kg 
over 10min, and can be maintained by an infusion of between 0.2 – 
0.7µ/kg/hr must be administered, diluted in 0.9% saline for infusion. 
Patients who receive dexmedetomidine in ICU were observed to be alert 
and arousable when stimulatd from sedation and rapidly return to their 
sleep like state. 
Caution: 
In patients with pre-existent bradycardia and conduction problems, in 
those with reduced ejection fraction (<30%) and in those who are 
hypovolemic.  
 
 
All the effects of dexmedetomidine can be antagonized by α2 antagonist, 
atipamezole which is a drug that reverses sedation and sympatholysis of 
dexmedetomidine and has a half life of 1.5 – 2hrs. 
Side effects: 
It crosses the placenta and hence it is not safe to be administered in 
pregnancy and in children. Common adverse effects include nausea, 
hypertension, hypotension ,  hypoxia, bradycardia, atrial fibrillation, and 
AV blocks. These adverse effects can be reduced by omitting or 
reducing the loading dose. 
 
 
 
 
 
 
 
 
Review of literature 
1. A study was conducted on seven healthy volunteers,where three 
brachial plexus procedures were administered using bupivacaine 0.25% 
and epinephrine 1µg/kg  a randomized double blinded cross over 
fashion. (a) control treatment:  this group received a local analgesic 
with 0.9% sodium chloride and saline. (b)intramuscular treatment: this 
group received local injection with 0.9% NaCl and im clonidine 2µg/kg 
and (c) block treatment: this group received local analgesic with 
clonidine 2µg/kg for block and an im injection of saline. The onset and 
duration of complete sensory and motor blockade was evaluated in the 
four nerve regions of forearm and hand. Additionally, sedation score, 
BP, HR and plasma clonidine concentration were determined. The 
median duration of sensory block was 270min (range 0 – 600) for the 
block treatment compared to 0min (range 0 – 400) for im treatment 
(P<0.05) and 0min (range0 – 100) for control treatment (P<0.05%).  
Similar results were obtained in motor blockade. Administration of 
clonidine resulted in sedation and decrease in HR and BP whatever be 
the route of administration. Plasma clonidine concentration was lower 
 
 
for the block compared to the im treatment and it was concluded that 
adding clonidine to bupivacaine and epinephrine prolongs and enhances 
the blockade. 
2. Eledjam jj  , Deschodt et al, Canadian journal of anaesthesia 1991: 
           This study compares the effect of adding alpha 2 agonist, 
clonidine and epinephrine to bupivacaine. In this study, 60 patients 
were randomly allocated into two groups, 30 patients receiving 150mics 
of clonidine and 30 patients receiving 200mics of epinephrine. No 
difference was found in the clonidine group in the onset of sensory and 
motor blockade compared to adrenaline. The duration of motor block 
was prolonged in clonidine group (580.4± 38.7 vs 290.6± 34.5) 
compared to adrenaline group. Block produced by adding clonidine was 
longer (994.2±34.2 vs 728 .3±5.8min) and superior to adrenaline. 
3. Dorothee M,Gaumann et al,Anaesthesia and Analgesia 1992: 
This study concluded that the enhancing effect of low dose clonidine 
(500M) on lignocaine (500M) induced inhibition of C-fibre action 
potential might explain the clinical observation that clonidine, at 
 
 
approximately thousand fold lower concentration prolongs the action of 
lignocaine in peripheral nerve block. 
4. Maze and Tranquil et al anaesthesiology 1999: 
         Alpha 2 adrenergic agonistic role in clinical anesthesia. This study 
concluded that clonidine has analgesic activity like a potent opoid, as 
anxiolytic and sedative as benzodiazepines, and sympatholysis. 
5. Henri Iskandar et al Anaesthesia analgeais 2000: The analgesic effect of 
clonidine as an analgesic for shoulder arthroscopy. This study reported 
that clonidine administered via an interscalene catheter enhanced 
analgesia compared with systemic administration. 
6. Wolfgang Erlacher et al, Canadian journal of anaesthesia 2001: 
This study compared the effect of clonidine as adjuvant for 
mepivacaine, bupivacaine and ropivacaine  in axillary & perivascular 
brachial plexus block. This study shows that the addition of clonidine 
has different impact on each of the three local anaesthetics investigated 
in terms of onset and duration of block. Mepivacaine group shows rapid 
onset compared to ropivacaine and bupivacaine group. The mepivacaine 
+ clonidine (468±  62min vs mepivacaine alone group(212± 82min), 
 
 
ropivacaine + clonidine (712 ± 82min) vs ropivacaine alone (702± 
52min), bupivacaine + clonidine (972± 72min) vs bupivacaine alone 
(728 v36min). 
7. a.Duma,B.Urbanek et al, Br.J.anaesthesia 2005: 
           A randomized control study with clonidine as an adjuvant to 
local anaesthetic in axillary approach of brachial plexus block,. 
8. Cucchiaro G, Ganesh A et al, Anasthesia analgesia 2007: 
The effects of clonidine on post-operative analgesia after peripheral 
nerve blockade in children. This study concluded that adding clonidine 
to ropivacaine and bupivacaine  can extend the sensory block and 
increase the duration of motor blocks. 
9. A study by Brunett et al. showed that dexmedetomidine enhancs the 
duration of bupivacaine anaesthesia and analgesia of sciatic nerve block 
without any damage to the nerve.  
10. Esmaoglu et al. added dexmedetomidine to levobupivacaine for 
axillary block and showed that the onset time of both sensory and motor 
block, prolongs the duration of the block and post-operative analgesia.  
 
 
11. Memis et al. in their study showed that addition of 
dexmedetomidine to lignocaine for IVRA improves both the quality of 
anesthesia as well as the intraoperative and postoperative analgesia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODOLOGY 
              This study was conducted on 50 patients undergoing upper 
limb surgeries aged between 15 & 55 yrs under supraclavicular block in 
Annal Gandhi Memorial Government Hospital attached to 
K.A.P.Viswanatham Government Medical college, Trichy. Informed 
written consent was obtained from each patient. Values were recorded 
using a preset proforma. It was a bouble blinded study in which patients 
were divided into two groups BD & BC comprising 25 each. Surgery 
was done under supraclavicular approach of brachial plexus block. 
Inclusion criteria: 
1.ASA grade – I & II 
2.Age between 15 & 55yrs 
Exclusion criteria: 
1.ASA grade – III & IV 
2.Patients with complications like severe anaemia, hypovolemia, 
septicemia, shock. 
 
 
3.Known case of hypersensitivity reaction to clonidine or 
dexmedetomidine. 
4.Bleeding disorders or on anticoagulant therapy  
5.Local infection at the site of puncture. 
Investigations required: 
• Hb%, TC,DC,BT,CT 
• Urine routine 
• Serum urea,sugar, creatinine 
• Chest x-ray, ECG 
• HIV,HBsAg 
Equipments for the procedure: 
For the procedure: 
A portable tray covered with sterile towel containing 
 Sterile syringes containing one 20ml and one 10ml. 
Hypodermic needles of 5cms length, 22G. 
Bowels containing povidone iodine and spirit. 
 
 
Sponge holding forceps. 
Towel and towel clips. 
Sterile gauze pieces. 
 
Fig. 10: Sterile tray containing drugs and equipments 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11: Drugs used for study 
 
 
For emergency resuscitation: 
The anaesthesia machine, emergency oxygen source (E type cylinder), 
pipeline oxygen supply, working laryngoscopes, appropriate size 
endotracheal tubes and connectors.  
Working suction apparatus with suction catheter. 
Oropharyngeal airways. 
Intravenous fluids. 
Drugs: Thiopentone sodium, propofol, midazolam, succinylcholine,  
glucopyllorate, atropine sulphate, adrenaline, deriphylline, 
dexamethasone, hydrocortisone, calcium gluconate and sodium 
bicarbonate. 
Monitors: 
Pulse oxymeter. 
Non invasive blood pressure monitor by sphygmomanometer on the 
opposite upper limb. 
 
 
 
Procedure: 
• After obtaining ethical committee approval, informed consent was 
obtained from the patients. Intravenous access was obtained, 
anaesthesia machine checked, resuscitative equipments and drugs 
were kept ready. Patients were allocated into the following two 
groups. 
• Group BD – received 35cc of 0.25% bupivacaine with 
dexmedetomidine 1µg/kg. 
• Group BC – received 35cc of 0.25% bupivacaine with clonidine 
1µg/kg. 
• Patient was made to lie in supine position, with the arms by the 
side and the head is turned slightly to the opposite side. 
• The interscalene groove and the midpoint of the clavicle were 
identified.  
• After strict aseptic precautions of the area, just above the midpoint 
of the clavicle, the subclavian artery pulsation was felt and 1.5 to 
2cms posterosuperior to it a skin wheel was raised with local 
anaesthetic. 
 
 
• A 22G, 5cms needle mounted on a 20ml syringe loaded with the 
drug was inserted at the same point in a backward, inward and 
downward direction. Either paresthesia was elicited or the first rib 
was encountered while injection. 
• If the first rib was encountered the needle was gently walked over 
the first rib until paresthesia was elicited in the arm or hand, after 
which the drug was injected following a negative aspiration of 
blood. 
• All the patients were monitored for anaesthesia and analgesia for 
24hrs post-operatively. 
• Sensory block was evaluated by eliciting temperature sensation 
using spirit soaked cotton over the distribution of the ulnar and 
median nerve, whereas a motor block was assessed by asking the 
patient to flex the forearm against gravity. 
 
 
 
 
 
Parameters observed: 
• Onset of sensory block: 
o This was taken as abolishment of temperature sensation over 
the distribution of the ulnar and median nerve and was 
assessed every minute after performance of the block. 
• Onset of motor blockade: 
      This was assessed every minute after the block using modified 
Bromage scale. Onset of motor block was considered when there was 
grade 1 motor blockade. 
o Grade 0: Full flexion and extension of elbow,wrist and fingers. 
o Grade 1: Weakness but able to move the arm. 
o Grade 2: Unable to move the arm but able to move the fingers. 
o Grade 3: Complete motor blockade  
• Duration of sensory block: 
o The pain was assessed using Visual Analogue Scale having 
10cms length. Patients were explained about the visual 
analogue scale as 0 as no pain and 10 as the worst possible 
pain and was asked about the score in the scale. Patients were 
 
 
observed every 30 minutes  till the surgery is over and hourly 
thereafter till 6 hrs, 2nd hrly for next 6 hrs and thereafter every 
3rd hrly  till 24 hrs. Time at which VAS score was 5 was noted 
and patient was given im NSAID. 
• Duration of motor blockade: 
o The time interval between the administration of local 
anaesthetic and the return of  complete motor function of the 
forearm and hand. 
• Vital parameters: 
o The pulse rate, blood pressure, O2 saturation were monitored 
every 15min till 1hr, 2nd hrly till 6 hrs and 6th hrly till 24hrs. 
• Sedation score: 
This was evaluated using Ramsay sedation score: 
• IM injection of  diclofenac sodium would be given as rescue 
analgesic when patient complains of pain. 
• Number of rescue analgesics in 24hrs of postoperative period 
would also be noted. 
• Quantitative data will be analysed using student’s unpaired ‘t’ test. 
 
 
• Qualitative data will be analysed by Fisher’s chi square test. 
• P value of <0.05 would be considered statistically significant. 
Patients in whom the block was unsuccessful, due to total 
failure or missed dermatomes who needed intravenous 
supplementation or general anaesthesia were excluded from the 
study.  
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
              50 ASA I & II of either sex aged 15-55yrs, posted for upper 
limb surgeries under supraclavicular brachial plexus block were selected 
for the study. The study was undertaken to evaluate the efficacy of 
dexmedetomidine (1µ/kg)  over clonidine(1µ/kg) as an adjuvant to 
bupivacaine (0.25%) for brachial plexus block. 
Table.1:Age Distribution 
Group MeancSD T value P value significance 
BC 36.8±12.26 
0.52 0.12 NS 
BD 34.88±9.03 
 
      The minimum age of the patient was 15yrs and the max age was 
55yrs. The mean age of the patient in group BC was 
36.8±12.26Bwas34.88±9. 
 
     
Table.
Group 
BC 
BD 
  
           
was 1
analysi
sensory
0.001) 
M
E
A
N
2:Onset 
M
1
8
     The m
1.14±1.13
s by stud
 block in
15
20
25
30
35
40
45
B
of Senso
ean±SD
1.14±1.1
.8±0.91 
ean tim
 and in
ent’s un
 group B
C
Grap
ry block
 T v
3 
8.0
e for ons
 group 
paired “t
D was s
BD
h.1: Age
(in min)
alue 
5 
et of sen
BD was 
” test sho
ignifican
 distrib
P valu
<0.001
sory blo
8.8±0.9
wed tha
tly faster
ution
e s
 H
ck was i
1min. Th
t the time
 than gro
 
ignifican
S 
n group 
e statist
 of onse
up BC (
age
 
ce 
BC 
ical 
t of 
p < 
 Table.
Group 
BC 
BD 
 
           
13.6±1
by stud
 test  sh
signific
M
E
A
N
3: Onset
M
1
1
   The m
.11 and 
ent’s unp
owed th
antly fas
0
5
10
15
20
B
 of Moto
ean±SD
3.6±1.11
1.36±0.9
ean time
in group 
aired “t”
at the tim
ter than g
C
Gra
r block (
 T v
 
7.6
52 
 for ons
 BD was
 
e of onse
roup BC
BD
ph.2: On
in min)
alue 
5 
et of mo
  11.36±
t of moto
 (p < 0.0
set of b
P valu
<0.001
tor bloc
0.952. T
r block i
01). 
lock
e s
 H
k in gro
he statist
n group B
se
m
ignifican
S 
up BC 
ical anal
D was 
nsory
otor
 
ce 
was 
ysis 
 
 
Table.4: Duration of Sensory block (in hours) 
Group Mean±SD T value P value significance 
BC 7.06±0.664 
11.9 <0.001 HS 
BD 9.3±0.667 
 
                 Patients of both groups were observed for 24hrs. The time 
was noted when the patient asked for rescue analgesics. The mean 
duration of sensory block in group BC was 7.06±0.664 and in group BD 
was 9.3±0.667hrs. The statistical analysis by student’s unpaired “t” test 
showed that the time of duration of sensory block in group BD was 
significantly faster than group BC (p < 0.001). 
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This was evaluated using Ramsay sedation score: 
1. Anxious and alert. 
2. Conscious and oriented. 
3. Sedated, responding to verbal commands. 
4. Responding only to mild physical stimulus. 
5. Responding to moderate & severe physical stimulus. 
6. Not arousable. 
          In group, sedation score corresponding to score 2 was observed in 
84% of patients and sedation score of 3 in 16% of patients, whereas in 
group BD, sedation score corresponding to 2 was observed in 20% of 
patients and sedation score of 3 in 80% of patients. The difference in 
sedation score between the two groups was found to be statistically 
significant by student’s unpaired ‘t’ test. (p<0.001). 
Hemodynamic variables: 
Pulse rate, systolic BP, diastolic BP and oxygen saturation was recorded 
at 0, 5, 15, 30 & 60min and 2, 6, 12 & 24hrs. 
 
 
 
Table 8: Pulse rate (beats/min) 
Time of 
assessment 
BC BD T 
value
P 
value 
significance
Mean SD Mean SD 
0min 79.240  7.008 78.880 6.760 0.854 0.020  NS 
5min 78.920  7.427 78.800 6.782 0.953 0.028  NS 
15min 78.320  7.284 78.480 7.148 0.938 0.014  NS 
30min 78.080  7.729 78.080 6.964 1.000 0.051  NS 
60min 77.840  7.888 78.240 6.888 0.849 0.033  NS 
2hrs 77.920  7.926 78.000 6.633 0.969 0.000  NS 
6hrs 78.480  7.880 78.280 7.481 0.927 0.092  NS 
12hrs 78.360  7.566 78.040 7.586 0.882 0.051  NS 
24hrs 78.480  7.600 78.040 7.552 0.838 0.013  NS 
 
           In group BC the mean pulse rate ranged from 73.920±9.9 to 
82.760±13.18beats/min and in group BD it ranged from 76.880±0.247 to 
81.92±8.11beats/min. The statistical analysis by student’s unpaired “t” 
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Table 9: Systolic BP(mmHg) 
Time of 
assessment 
BC BD T 
value
P 
value 
significance
Mean SD Mean SD 
0min 123.44  8.515 120.480 7.922 0.209 0.067  NS 
5min 123.28  8.244 120.320 7.993 0.204 0.042  NS 
15min 123.28  8.163 119.920 7.884 0.145 0.016  NS 
30min 123.04  8.023 118.880 8.167 0.075 0.073  NS 
60min 122.72  7.547 119.040 7.961 0.100 0.002  NS 
2hrs 122.16  6.479 119.120 7.748 0.139 0.067  NS 
6hrs 121.2  7.141 119.760 7.557 0.492 0.013  NS 
12hrs 121.92  7.604 120.000 7.483 0.373 0.003  NS 
24hrs 122.48  7.644 120.080 7.449 0.266 0.033  NS 
          
  In group BC the mean systolic BP ranged from 122.56±9.05 to 
124.08±7.77mmHg and in group BD it ranged from 116.24±7.53 to 
121.36±9.12mmHg. The statistical analysis by student’s unpaired “t” 
 test sh
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Table 10:Diastolic BP(mmHg) 
Time of 
assessment 
BC BD T 
value 
P 
value  
significance
Mean SD Mean SD 
0min 75.92  4.949  76 7.348 0.964 0.064  NS 
5min 75.84  5.064  75.76 7.242 0.964 0.099  NS 
15min 75.52  5.009  75.52 6.514 1.000 0.013  NS 
30min 74.56  5.116  75.28 6.680 0.671 0.012  NS 
60min 74.16  4.652  74.88 6.809 0.664 0.059  NS 
2hrs 74.4  4.796  74.96 6.761 0.737 0.106  NS 
6hrs 74.48  5.009  75.44 6.795 0.572 0.180  NS 
12hrs 75.08  5.212  75.68 7.134 0.736 0.122  NS 
24hrs 75.6  5.196  75.68 7.134 0.964 0.158  NS 
              In group BC the mean diastolic BP ranged from 71.36±5.73 
to75.92±4.94mmHg and in group BD it ranged from 71.04±6.19 
to76.48±7.6mmHg. The statistical analysis by student’s unpaired “t” test 
showed that there was no significant difference in diastolic BP between 
the 2 groups(p>0.05). 
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Table 11:Oxygen saturation(%) 
Time of 
assessment 
BC BD T 
value
P 
value 
significance
Mean SD Mean SD 
0min 99.28 0.541 99.2 0.707 0.655 0.478 NS 
5min 99.4 0.577 99.4 0.707 1 0.204 NS 
15min 99.48 0.509 99.44 0.506 0.782 0.367 NS 
30min 99.2 0.577 99.2 0.633 1 4.654 NS 
60min 99.28 0.458 99.32 0.485 0.782 0.236 NS 
2hrs 99.44 0.583 98.92 0.483 0.002 0.127 NS 
6hrs 99.08 0.493 99.28 0.452 0.151 0.265 NS 
12hrs 99.04 0.538 99.04 0.196 0.196 0.371 NS 
24hrs 99.12 0.6 99.12 0.543 0.257 0.612 NS 
 
             In group BC the mean O2 saturation ranged from 99.04±0.53 to 
99.04±0.19% and in group BD it ranged from 99.04±0.19 to 
99.92±0.48%  . The statistical analysis by student’s unpaired “t” test 
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DISCUSSION 
         Brachial plexus provides post-op analgesia only for a short 
duration even when we use longer acting LA agents like bupivacaine. 
Hence, various adjuvants like opioids, midazolam, neostigmine,etc, have 
been evaluated to prolong the duration of analgesia. The newer drugs 
clonidine and dexmedetomidine were found to produce anti-nociception 
when used intrathecally and epidurally.  
                    Hence these drugs were used as an attempt to assess the 
efficacy of dexmedetomidine over clonidine as an adjuvant to 
bupivacaine in brachial plexus block. They were compared in terms of 
onset time, duration of analgesia and sedation. Hemodynamic variables 
and no of rescue analgesics in first 24hrs were also studied. 
                 A total of 50 patients in the age group of 15-55yrs were 
included in the study, 25 in each group. Out of which the mean age of 
group BC (receiving bupivacaine with clonidine) was 36.8±12.26yrs and 
the mean age of group BD (receiving bupivacaine with 
 
 
dexmedetomidine) was 34.88±9.03yrs. hence both the groups were 
comparable in regard to age.  
                 In our study, it was found that the onset of sensory block and 
motor block were significantly faster in patients who received a 
combination of bupivacaine and dexmedetomidine than the combination 
of bupivacaine and clonidine. Onset of sensory block ( group BC-
11.14±1.13min : group BD-8.8±0.192min). Onset of motor block (group 
BC-13.6 ±1.22min:group BD – 11.36±0.9min). 
               Clonidine was used previously  for its antihypertensive 
properties. The central actions are mediated through α2adrenoceptors, 
which are situated at locus coeruleus and the dorsal horn of spinal cord. 
But, specific peripheral effects of clonidine appear to be less obvious 
because these adrenoceptors are not present on the axon of the normal 
peripheral nerve(19).  Four mechanisms have been proposed for the action 
of clonidine in peripheral nerve blocks. They include centrally mediated 
analgesia, vasoconstrictive effects via α2 β adrenoceptor receptors , 
direct action on peripheral nerve and attenuation of inflammatory 
response(22).  The direct action of clonidine on the nerve can be 
 
 
explained on the basis of a study conducted by Dalle et al. They 
proposed that clonidine, by enhancing activity-dependent 
hyperpolarisation generated by the Na/K pump, increases the threshold 
for initiating the action potential causing slowing or blockage of 
conduction. 
    Popping et al. in their metaanalysis of randomized controlled study 
showed that the beneficial effect of clonidine on the duration of 
analgesia was observed with all tested local anaesthetics(19). 
A study by Brumett et al. showed that dexmedetomidine increases the 
duration of bupivacaine anaesthesia and analgesia without any damage 
to the nerve. The histopathological evaluation of these nerve axons were 
normal in both the control and combination groups. 
               In another study, the analgesic effect of peripheral perineural 
dexmedetomidine added to ropivacaine prolonged the duration of 
analgesia by enhancement of the hyperpolarisation-activated cation 
current, which prevents the nerve from returning from a hyperpolarized 
state to resting membrane potential for subsequent firing(30). Clonidine 
 
 
also inhibits compound action potential(CAPs) but the maximum effect 
of clonidine was only 20%. 
                       Esmaoglu et al. added dexmedetomidine to levobupivacaine 
for axillary block and showed that it shortens the onset of both sensory 
and motor block and prolongs the duration of the block and post-
operative analgesia(28). This may be due to reduced release of 
norepinephrine, leading to α2 receptor  - independent inhibitory effects 
on nerve fibre action potential. Similarly, in our study also, we found 
that the onset of sensory and motor block was faster in group BD 
compared to group BC, which was statistically significant. The duration 
of analgesia was also found to be prolonged in group BD than group BC. 
               In our study, we compared the addition of clonidine (Group BC 
1 μg/kg) and dexmedetomidine (Group BD 1 μg/kg) to bupivacaine in  
brachial plexus block. The result of our study shows that all patients in 
both groups were comparable with respect to demographic profile. With 
these doses, we had stable haemodynamics in patients in both the groups. 
 
 
             None of the patients in Group BD required sedation 
intraoperatively and they were comfortable throughout the surgery with 
arousable sedative effects. This can be explained on the basis that some 
amount of systemic absorption of drug could be present.  As α2 agonists 
produce sedation by central action, they produce inhibition of substance 
P release at the level of the dorsal root neuron and by activation of 
α2 adrenoreceptor in locus coeruleus.  
                 
                 From this study, we would like to suggest that 
dexmedetomidine can be safely used with local anaesthetic in peripheral 
nerve blocks, however, further trials to determine the exact dose and 
effect of neurotoxicity on the human nerve are required. 
 
 
 
 
 
 
 
CONCLUSION 
               To conclude, we would like to state that dexmedetomidine 
prolongs the duration of sensory and motor block as compared with 
clonidine when it is used as an adjuvant to Bupivacaine in peripheral 
nerve block. 
Hence it is seen that dexmedetomidine when added to bupivacaine 
compared to clonidine has 
1. Faster onset of sensory block 
2. Faster onset of motor block 
3. Prolonged duration of sensory block 
4. Prolonged duration of motor block 
5. Less no of rescue analgesics in post-op 24hrs 
6. Comfortable sedation where the patient can be arousable at any time 
7. No significant difference in hemodynamic variables. 
 
 
 
 
SUMMARY 
            This study, “A clinical comparison between dexmedetomidine 
and clonidine with bupivacaine in brachial plexus block by 
supraclavicular approach” was conducted in 50 patients of either sex, in 
the range of 15 – 55yrs. ASA grade I & II, admitted in 
K.A.P.Viswanatham Government Hospital, Trichy for upper limb 
surgeries from 2010 – 2013. They were randomly divided into two 
groups; 
Group BC :  received 35ml of 0.25% bupivacaine with clonidine 1µg/kg 
Group BD : received 35ml of o.25% bupivacaine with dexmedetomidine 
1µg/kg  
The following parameters were recorded and compared: 
• Onset of sensory block and motor block 
• Duration of sensory block and motor block 
• No of rescue analgesic doses in post-op 24hrs 
• Sedation score 
 
 
• Hemodynamic variables like pulse rate, systolic BP, diastolic BP and 
oxygen saturation. 
• Onset of sensory and motor block:  
            The mean time for onset of sensory block was in group BC was 
11.14±1.13min  and in group BD was 8.8min. The mean time for onset 
of motor block in group BC was 13.6±1.11 and in group  BD was  
11.36±0.952min. 
            Both differences were statistically significant (p<0.05). 
Duration of sensory and motor block:  
            The mean duration of sensory block in group BC was 7.06±0.664 
and in group BD was 9.3±0.667hrs. 
            The mean duration of motor  block in group BC was 
6.66±0.657and in group BD was  8.5±0.692hrs. 
           Both the differences were statistically significant (p<0.05). 
 
 
 
 
Rescue analgesic requirement in post-op 24hrs: 
             In group BC 20% required one rescue analgesic dose and 80% 
required 2 analgesic doses, whereas in group BD, 56% required one 
analgesic dose and only 44% required 2 analgesic doses. The rescue 
analgesic doses required by group BD was significantly higher (p<0.05). 
Sedation score: 
                  In group BC, 20% of  patients at 15min, 32% at 30min & 
26% at 60min had sedation score of 2. In group BD, 66% at 15min, 
100% at 30min, 80% at 60min and 16% at 2hrs had a sedation score of 
2, both responding to verbal stimulus. Statistical analysis by Chi-square 
test showed that the difference in sedation score was significant 
(p<0.05). 
Hemodynamic variables: 
           Both the groups were comparable with regard to pulse rate, 
systolic BP, diastolic BP and oxygen saturation. There was no 
statistically significant difference (P>0.05).  
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1 Settu pillai 49 M 51068 72 II 10 12 6 6 2 0 86 86 85 82 86 86 86 80 86 120 120 120 120 120 120 120 120 122 80 80 80 78 78 80 80 80 80 98 99 100 100 100 99 100 100 100
2 Sakthivel 50 M 57298 69 II 10 12 7 6 2 2 94 94 94 96 96 96 96 95 94 120 122 122 122 122 122 120 120 122 80 80 78 78 76 76 76 76 76 100 99 100 100 100 99 100 100 100
3 Surshkumar 28 M 2423 42 I 12 14 7 7 2 2 78 76 75 74 74 74 74 76 76 120 120 120 118 118 118 118 120 120 70 70 70 70 70 70 70 70 70 100 99 100 100 100 99 100 100 100
4 Elangovan 32 M 5655 55 I 11 15 8 8 2 2 84 84 82 82 80 80 84 84 84 126 126 126 124 124 124 124 126 126 78 78 78 76 76 76 78 78 78 99 99 100 100 100 100 100 100 100
5 Ganesan 38 M 59309 52 I 12 13 9 8 1 2 98 98 96 96 96 96 98 98 98 130 130 128 128 128 128 130 130 130 80 80 80 78 78 80 80 80 80 99 99 99 100 100 100 99 99 99
6 Palanavel 42 M 9057 70 II 13 14 7 7 2 3 80 80 80 80 82 82 80 80 80 130 130 138 138 138 130 130 130 130 80 80 80 80 78 78 78 78 78 99 99 99 100 100 100 99 99 99
7 Simon 40 M 11610 67 I 11 14 8 7 2 2 82 82 80 80 82 82 82 82 80 110 110 110 110 110 110 110 110 110 70 70 70 70 70 68 68 69 68 99 98 99 99 99 100 99 99 99
8 Shanthi 38 F 16328 66 I 12 13 7 6 1 2
70 66 66 66 68 68 66 66 66 120 120 120 118 118 118 120 120 120 70 70 70 68 68 70 70 70 80
99 100 99 99 99 100 99 99 99
9 Natarajan 55 M 16564 78 I 11 15 7 6 2 2 84 84 80 80 80 80 84 84 84 110 110 110 120 122 122 110 110 110 80 80 80 78 78 80 80 80 80 100 100 99 99 99 98 99 99 99
10 Tamilarasan 21 M 23524 54 I 12 14 7 7 2 2 76 76 74 74 74 78 78 78 78 120 120 120 118 118 118 116 120 120 80 80 80 78 76 76 76 80 80 100 100 99 99 99 99 99 99 99
11 Ayyappan 37 M 25278 80 I 10 12 8 8 2 2 73 72 70 73 73 72 72 72 72 130 130 130 130 130 128 120 120 120 70 70 70 68 70 70 70 70 70 100 99 99 99 99 99 99 99 99
12 Marikannu 41 M 34735 79 I 10 14 8 7 1 2 82 82 84 84 84 84 82 82 82 130 130 130 128 122 128 130 128 128 80 80 80 80 80 80 80 80 82 100 99 99 99 99 99 99 99 99
13 Sarathkumar 16 M 36304 35 I 10 13 7 7 1 2 78 78 78 78 70 70 78 78 78 120 120 122 122 120 120 120 120 120 80 80 80 80 80 80 80 82 82 100 99 99 99 99 99 99 99 99
14 Malathi 39 F 42587 72 I 11 13 8 7 2 3
79 78 76 76 76 78 78 78 78 130 130 130 132 130 130 130 130 130 70 70 68 68 68 68 66 66 68
100 99 99 99 99 99 99 99 99
15
Balasubrama
nian
22 M 43730 36 I 12 15 7 6 2 2
77 76 75 77 77 76 76 76 76 120 120 120 118 116 116 120 120 120 70 70 70 68 68 68 68 68 68
99 99 99 98 99 99 99 99 100
16 Saravanan 32 M 48820 64 I 12 14 6 6 1 2 81 80 82 82 82 82 80 80 80 110 110 110 110 114 114 112 112 112 70 70 70 68 70 70 70 70 70 99 99 99 98 99 99 99 99 100
17 Mariammal 43 F 54783 77 II 10 12 7 6 2 2
86 88 88 88 86 86 86 86 86 140 140 140 140 138 130 130 138 138 80 80 80 80 78 78 78 80 80
99 99 99 99 99 99 99 98 98
18 Velankanni 33 M 54631 65 I 13 14 8 7 1 3 78 78 78 78 76 76 76 76 76 130 130 130 128 128 128 128 128 128 80 80 80 80 78 78 78 78 78 99 100 100 99 99 99 98 98 98
19 Rangasamy 19 M 9049 34 I 12 15 7 7 2 2 72 72 72 68 68 68 70 70 70 120 120 120 120 122 120 120 120 120 80 80 80 76 76 76 76 76 76 99 100 100 99 99 100 98 98 98
20 Panneerselvi 32 F 20197 56 I 11 14 9 7 2 2 74 74 74 74 74 70 70 70 70 130 130 130 128 128 128 128 130 130 80 80 78 78 78 80 80 80 80 99 100 100 99 99 100 99 99 99
21 Shanmugam 70 M 21716 82 I 10 13 8 8 2 2 76 76 76 76 74 74 74 76 76 140 138 130 130 130 130 130 130 130 80 80 78 78 78 76 76 80 80 99 100 100 99 99 100 99 99 99
22 Pitchai 45 M 34530 77 I 10 12 8 7 1 2 77 77 77 78 78 78 76 76 76 120 120 120 120 118 118 118 120 120 70 68 68 68 66 66 66 68 68 99 100 100 99 99 100 99 99 99
23 Banumathy 37 F 42844 68 I 11 13 7 6 1 3 70 70 70 70 70 72 72 72 72 120 120 120 118 118 118 116 116 120 70 70 70 68 68 70 70 70 70 99 100 100 99 99 100 99 99 99
24 Baskar 40 M 41308 78 I 12 14 7 7 2 2 78 78 78 76 76 76 78 78 78 110 110 110 108 108 108 106 106 106 80 80 80 80 78 76 78 78 78 99 100 100 99 99 100 99 99 99
25 Suresh 21 M 45106 43 I 14 16 8 7 2 2 68 68 68 64 64 64 66 66 66 130 126 126 128 128 128 124 124 130 70 70 70 70 70 70 70 70 70 99 100 100 100 100 100 99 99 99
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1 Balaji 27 M 51068 58 I 8 11 10 9.5 2 2 78 78 76 74 76 74 78 78 78 118 118 118 116 116 116 118 118 118 70 70 70 68 70 70 70 70 70 100 100 100 99 99 99 99 99 99
2 Sikkan 50 M 56840 67
III/
E 9 12
10 9 2
3 80 80 78 78 78 76 80 70 70 134 134 134 132 132 134 134 134 134 74 74 74 76 76 74 74 76 76 100 99 99 99 99 100 100 100 100
3 Kumar 30 M 37569 55 I
8 12
10 9 1
3 84 84 86 86 86 86 84 84 84 120 120 120 118 118 118 120 120 120 80 80 80 76 76 80 80 80 80 100 100 100 100 100 100 99 99 99
4 Logeswari 35 F 442 56 II
8 12
9 8.5 1
3 88 88 88 88 86 84 88 88 88 122 122 122 120 120 122 122 122 122 78 78 78 78 76 76 78 78 78 100 100 100 99 99 99 100 99 99
5 Saleem 32 M 5595 55 I
9 11
9 8.5 2
3 80 80 80 80 82 82 80 80 80 134 134 134 134 134 130 130 130 130 88 88 86 86 88 88 88 88 88 100 100 100 99 99 99 100 99 99
6
Panneer 
selvam
40 M 8213 60 I
9 10
10 8.5 2
2 86 86 86 86 84 84 89 89 87 120 120 118 118 118 120 120 120 120 70 70 70 70 68 68 70 68 68 100 100 100 99 99 99 100 99 99
7 Karthik 24 M 11376 45 I
10 10
10 9.5 1
3 72 72 70 70 70 70 68 68 70 118 118 116 116 120 120 120 120 120 68 68 70 70 68 68 68 68 68 99 100 100 99 99 99 100 99 99
8 Saroja 37 F 14152 50 I 9 13 10 9 1 3 78 76 76 76 74 74 74 76 76 124 124 124 124 120 120 124 124 124 80 78 78 76 80 80 80 80 80 99 100 100 99 99 99 100 99 99
9 Suresh 35 M 18048 63 I 8 12 9 8 1 3 68 68 64 64 64 68 68 68 68 112 112 112 110 110 112 112 112 112 78 78 78 76 76 76 78 78 78 99 100 100 100 100 99 100 99 99
10
Palaniam
mal
30 F 22229 50 I
8 11
8 7.5 2
3 74 74 74 74 78 78 78 76 76 118 116 116 116 114 114 114 116 116 70 70 70 70 70 70 70 70 70 99 100 100 100 100 99 99 99 99
11 Rajesh 16 M 24612 40 I 9 12 8 7.5 2 3 90 90 90 86 88 88 90 90 90 120 120 120 118 118 118 118 118 118 76 76 76 78 78 78 78 78 78 98 98 100 100 100 99 99 99 99
12 Ramasamy 40 M 27608 70 II
9 11
10 9 1
3 86 86 86 84 84 84 86 86 86 110 110 110 108 108 108 110 110 110 66 66 66 64 64 64 66 66 66 98 98 100 100 100 99 99 99 99
13
Gracy 
gnanamar
y
40 F 33396 60 II
9 10
10 9.5 2
2 86 86 86 84 84 84 84 84 84 112 112 110 110 112 112 112 112 112 78 78 78 74 74 78 78 78 78 98 98 99 100 100 99 99 99 100
14
Chandrase
kar
35 M 33599 55 I
10 10
11 9.5 2
3 80 80 80 80 82 82 80 80 82 118 118 118 116 116 116 116 116 118 76 76 76 76 76 76 76 76 76 98 99 99 100 100 98 99 99 100
15 Karolin 46 F 37874 48 I 8 13 10 9 1 3 72 72 72 72 70 70 70 70 70 110 110 110 106 106 106 108 110 110 70 70 70 68 70 70 70 70 70 99 99 99 100 100 98 99 99 100
16
Rajalaksh
mi
50 F 44791 60 I
8 12
9 8 1
3 76 76 76 76 76 74 76 76 76 130 130 130 130 130 130 128 130 130 90 88 88 86 86 88 88 88 88 99 99 99 98 99 98 99 99 100
17 Gopi 37 M 52365 56 I 8 11 9 7.5 1 3 76 76 76 76 76 76 74 74 74 120 120 120 122 122 120 120 120 120 78 78 78 78 76 76 78 78 78 99 99 99 98 99 98 99 99 98
18 Sivakumar 41 M 6732 54 I 9 13 9 8.5 2 2 78 78 78 76 76 76 78 78 78 118 118 118 116 118 118 118 118 118 70 70 70 70 68 68 68 68 68 99 99 99 98 99 99 99 99 98
19
Sathishku
mar
30 M 18020 45 I
9 12
10 9.5 2
3 70 70 74 74 74 74 70 70 70 120 120 120 118 120 120 120 120 120 80 80 80 86 86 80 80 80 80 99 99 99 99 99 99 99 99 99
20
Mohd.Saff
iullah
18 M 24765 50 I
10 11
11 10 1
3 86 86 86 86 84 84 86 86 86 138 138 138 136 136 136 138 138 138 90 90 90 90 88 88 90 90 90 99 99 99 99 99 99 99 99 99
21
Mohanava
lli
39 F 31817 55 II
11 11
10 8.5 2
3 68 68 68 70 70 70 68 68 68 118 116 116 116 116 118 118 118 118 68 68 68 70 70 70 70 70 70 99 99 99 99 99 99 99 99 99
22
Mohamm
ed Ali
49 M 46601 76 I
7 11
9 8.5 1
3 78 78 76 76 78 78 78 78 78 120 120 120 120 118 116 120 120 120 78 78 78 78 70 70 70 70 70 99 100 99 99 99 99 99 99 99
23 Balu 35 M 45130 50 I 8 12 9 8 1 2 90 90 90 92 92 92 90 90 90 112 112 112 112 114 114 112 112 112 66 66 68 68 68 68 68 68 68 100 100 99 99 99 99 99 99 99
24 Ganesan 24 M 46913 52 I 9 11 9 8.5 2 3 78 78 76 76 76 74 74 78 78 134 134 130 130 130 130 130 130 130 88 88 80 80 80 80 80 86 86 100 100 99 99 99 99 99 99 99
25 Manjula 31 F 47491 42 I 10 10 10 9 1 3 70 70 70 68 68 68 66 66 64 112 112 112 110 110 110 112 112 112 70 68 68 70 70 70 70 70 70 100 100 99 99 99 99 99 99 99
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ANNEXURE-1 
        PROFORMA 
COMPARISON OF DEXMEDITOMEDINE WITH CLONIDINE AS AN 
ADJUVANT TO BUPIVACAINE IN SUPRACLAVICULAR  
BRACHIAL PLEXUS BLOCK 
 
NAME:                                        AGE/SEX:                       IP.No:                     
ADDRESS:                                  WEIGHT:                         ASA Gr: 
                                                    GROUP: 
                                                    DIAGNOSIS/SURGERY:                                                                                                                                   
  
General physical examination: 
PR:                                  BP:                                 RR: 
Objectives: 
Time of injection:          min. 
Onset of sensory block:            min. 
Onset of motor block:          min.            
 
 
 Monitoring: 
Time in 
Hrs 
PR BP SPO2 Sedation 
score 
VAS 
score 
      
      
      
      
      
      
      
      
      
      
 
 
Duration of surgery in hrs: 
Duration of sensory analgesia: 
Duration of post-op analgesia: 
No of rescue analgesics in postop 24hrs: 
 
 

